Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AD 4

Next Previous
X
Search
Drug Profile

AD 4

Alternative Names: L-2-Acetamido-3-mercaptopropionamide; N-Acetylcysteinamide; N-Acetylcysteine amide; AD-4; NACA

Latest Information Update: 24 Jan 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Eucalyptus Ltd; Yissum Research Development Company
  • Class Eye disorder therapies; Neuroprotectants; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antioxidants; Chelating agents; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurodegenerative disorders

Most Recent Events

  • 09 Jan 2008 Preclinical trials in Neurodegenerative disorders in USA (PO)
  • 09 Jan 2008 AD 4 exclusively licensed to Eucalyptus Ltd. worldwide for the treatment of Neurodegenerative disorders
  • 24 Apr 2007 No development reported - Preclinical for Neuroprotection in Israel (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top